Gracell Biotechnologies, Inc. (NASDAQ:GRCL) Q4 2020 Earnings Conference Call March 10, 2021 08:00 AM ET Company Participants Kevin Xie - Chief Financial Officer Dr. .cls-1 { SUZHOU and SHANGHAI, China, March 31, 2021 /PRNewswire/ — Gracell Biotechnologies Inc. (NASDAQ: GRCL) ("Gracell"), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of cancer, announced that they have enrolled the first patient in their pivotal Phase 1/2 clinical study of GC007g, an allogeneic . .cls-2, He served as elected Chairman of AIMA Hong Kong (global trade association for hedge funds) for 8 years between 2004 and 2012, and was appointed by the HKSAR government to the Securities and Futures Commission (SFC) advisory committee from 2007 to 2009 and the Financial Services Development Council (FSDC) from 2013 to 2019. Stock analysis for Gracell Biotechnologies Inc (GRCL:NASDAQ GS) including stock price, stock chart, company news, key statistics, fundamentals and company profile. Dr. Sersch holds an M.D. A high-level overview of Gracell Biotechnologies Inc. (GRCL) stock. Prior to founding Gracell, Dr. Cao co-founded Cellular Biomedicine Group, Inc. (formerly Nasdaq: CBMG), a formerly Nasdaq-listed company engaged in the development of proprietary cell therapies for the treatment of cancer and degenerative diseases, and served as COO, CEO and director from August 2010 to January 2016. Jefferies Thinks Gracell Biotechnologies' Stock is Going to Recover Aug. 18, 2021 at 8:26 a.m. Earnings Summary (NYSE:AIR) AAR last issued its quarterly earnings results on September 22nd, 2021. Gracell Biotechnologies is registered under the ticker NASDAQ:GRCL . Their stock opened with $19.00 in its Jan 8, 2021 IPO. Dr. Xie holds a Ph.D. in chemistry from The City University in New York, and an M.B.A in finance from The Wharton School, University of Pennsylvania. Mr. Lee is a graduate of the University of Pennsylvania. Golden Biotechnology Corporation (GBC), founded by Mr. Sheng Yung, Liu in 2002, is an leading and innovative drug discovery and evidence-based healthy food supplement manufacturing company dedicated to enhancing lives by developing high quality products that prevent and treat diseases. Dr. Cao holds a Bachelor’s degree in Medicine from Fudan University Medical College in Shanghai, China and a Ph.D. in Pharmacology from The Medical College of Virginia, U.S. Dr. Cao also has over 80 issued patents and applications for advanced cell therapies. You owe it to yourself to dive into the pages of this incredible self-help resource promoting personal growth and mind-body-soul skill development through awareness and balance. This book is a game changer. Prior to that, Dr. Sersch served as Executive Medical Director at Amgen Inc. leading the early and late stage clinical development for hematological malignancies. Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act. Dr. Xu has been a professor of Ophthalmology and Pharmacology at Tongji University School of Medicine (TUSM) since 2008 and a director of The East China Stem Cell Bank located inside TUSM, a center for stem cell research and clinical application in China. . © 2021 Verizon Media. .cls-2, Xi-Yong (Sean) Fu . Gracell Biotechnologies Inc.’s ISS Governance QualityScore as of N/A is N/A. Mr. Lee serves as an Independent Non-Executive Director to Goldstream Investment Ltd. (HKEX 1328.HK). ET on TipRanks.com All You Need to Know About Gracell Biotechnologies Inc. Leveraging its pioneering FasTCAR and TruUCAR technology platforms, Gracell is developing a rich clinical-stage pipeline of multiple autologous and allogeneic product candidates to overcome major . } In Stem Cells in Regenerative Medicine: Methods and Protocols, leading experts in the field provide an updated representation of the landscape of stem cell-based therapies in a wide spectrum of tissue systems and ontogenic stages, from the ... Gracell Biotechnologies is a clinical stage CAR-T focused company. Gracell Biotechnologies Second Quarter 2021 Earnings Call. GBC's main focus is on new drug R&D . Gracell Biotechnologies Inc. published this content on 10 September 2021 and is solely responsible for the information contained therein. Found insideAlthough biotechnology has produced many benefits for humanity, the exploitation of the planet's natural resources has also resulted in some undesirable consequences such as diminished species biodiversity, climate change, environmental ... In addition, it has a portfolio of earlier stage product candidates targeting various cancer indications, such as ovarian cancer, breast cancer, peripheral T cell lymphoma, a subtype of NHL, and T cell lymphoblastic leukemia. Gracell Biotechnologies to Report Second Quarter Financial Results on Tuesday, August 17, 2021 Terms and conditions . Dr. Xu has been an independent director of Guangzheng Group Co., Ltd., a company listed on the Shenzhen Stock Exchange (Stock Code: 002524) and Zhejiang Shapuaisi Pharmaceutical Co., Ltd., a company listed on the Shanghai Stock Exchange (Stock Code: 603168), since June 2018 and August 2020, respectively. Gracell Biotechnologies Inc is a China-based clinical-stage biopharmaceutical company focused on discovering and developing cell therapies for the treatment of cancers. Gracell Biotechnologies, a Phase 1 Chinese biotech developing CAR-T cell therapies for cancer, announced terms for its US IPO on Monday. At Amgen, Dr. Sersch successfully led global filing activities for a multiple myeloma drug within the FDA’s novel rolling submission program. Gracell Biotechnologies Inc - ADR () Stock Market info Recommendations: Buy or sell Gracell Biotechnologies Inc - ADR stock? Earnings for Gracell Biotechnologies are expected to decrease in the coming year, from ($0.25) to ($0.39) per share. It will be an invaluable reference for all practicing hematologists, oncologists and pathologists.Atlas of Differential Diagnosis in Neoplastic Hematopathology, Second Edition discusses:basic clinical data Gracell Biotechnologies Signs Exclusive License Agreement with FutureGen Biopharm to Develop Engineered Immune Cell Therapies Targeting Claudin 18.2 in Solid Tumors Aug 3 2021. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A. Gordon Freeman. Found insideMedical Innovation: Concept to Commercialization is a practical, step-by-step approach on how to move a novel concept through development to realize a commercially successful product. Distributed by Public , unedited and unaltered, on 10 September 2021 16:01:05 UTC . Ms. Hayes later served as the China expert and led inspections for the Public Company Accounting Oversight Board (PCAOB), an organization established by the United States Congress and overseen by the Securities and Exchange Commission (SEC). Founder, Chairman, and Chief Executive Officer. Annovis Bio, Gracell Biotechnologies leads healthcare gainers; Precipio, Cullinan Oncology among major losers . This book presents selected articles from the International Conference on Asian and Pacific Coasts (APAC 2019), an event intended to promote academic and technical exchange on coastal related studies, including coastal engineering and ... Q2 2021 Earnings Presentation. Gracell Biotechnologies Inc. ("Gracell") is a global clinical-stage biopharmaceutical company dedicated to discovering and developing breakthrough cell therapies. Sponsored ADR (GRCL . Building 12, Block BPhase II, Biobay Industrial Park 218 Sangtian Street Suzhou Industrial ParkSuzhou 215123China86 512 6262 6701http://www.gracellbio.com, Sector(s): HealthcareIndustry: BiotechnologyFull Time Employees: 202. Dr. Wang has over 20 years of experience in the healthcare industry. William Cao, founder and chief executive officer of Gracell Biotechnologies, discusses the Shanghai-based company's initial public offering in the U.S. and . Dr. Wang has served as Partner and Senior Managing Director, Asia of OrbiMed Advisors LLC, since August 2011. Distributed by Public , unedited and unaltered, on 10 September 2021 16:01:05 UTC . He is also an advisor to HK-X Tech and Beyond Ventures. Description. From the classic Margarita to the Love Byte, "Cocktail Chameleon" is award-winning designer and producer Mark Addison's invitation to join him as he dresses up twelve cocktails in twelve unique variations for 144 signature takes on the ... Gracell Biotechnologies, a Phase 1 Chinese biotech developing CAR-T cell therapies for cancer, raised $209 million by offering 11 million ADSs at $19, above the range of $16 to $18. Gracell is developing cell and gene therapies that deliver fast, deep and durable responses for cancer patients, Our autologous platform producing CAR-T cell therapies that utilize next-day manufacturing to deliver younger, less exhausted T cells with enhanced activities, Our allogeneic platform generating CAR-T cell therapies that are readily available off-the-shelf at lower cost for a broad patient base, We are developing a rich clinical-stage pipeline to unlock the long-held promise of CAR-T cell therapies, Gracell Biotechnologies Reports Second Quarter 2021 Unaudited Financial Results and Provides Corporate Update, Gracell Biotechnologies Signs Exclusive License Agreement with FutureGen Biopharm to Develop Engineered Immune Cell Therapies Targeting Claudin 18.2 in Solid Tumors, Gracell Biotechnologies to Report Second Quarter Financial Results on Tuesday, August 17, 2021, .cls-1{fill:#bcbec0}.cls-2,.cls-5{fill:#fff}.cls-2,.cls-3{fill-rule:evenodd}.cls-3,.cls-4{fill:#ef4123}. Gracell Biotechnologies's SIR currently stands at 15.33. .cls-4 { from Peking University School of Medicine, and a Ph.D. in Developmental Biology from California Institute of Technology. In Animal Models for Stem Cell Therapy: Methods and Protocols, expert researchers in the field detail disease models of hepatic, cardiovascular, neurological diseases, connective and contractile tissue. In this Book, an attempt is made to offer an insight on the common molecular techniques that are in use and recent advances in molecular diagnostics. Gracell Biotechnologies Inc., a clinical-stage biopharmaceutical company, primarily discovers and develops cell therapies for the treatment of cancer in the People's Republic of China. The company was founded in 2017 and is headquartered in Suzhou, China. Gracell Biotechnologies Inc is a China-based clinical-stage biopharmaceutical company focused on discovering and developing cell therapies for the treatment of cancers. The aerospace company reported $0.52 earnings per share for the quarter, topping analysts' consensus estimates of $0.49 by $0.03. Gracell Biotechnologies to Report Second Quarter Financial Results on Tuesday, August 17, 2021 Terms and conditions . CEO - Zelluna Immunotherapy. This acclaimed book describes the convergence of scientific, policy, regulatory, and commercial factors that drive the biotechnology industry and define its scope. Leveraging its pioneering FasTCAR and TruUCAR technology platforms, Gracell is developing a rich clinical-stage pipeline of multiple autologous and allogeneic product candidates with the potential to . Cayman Islands. A modern song retells the fable of a frustrated fox that, after many tries to reach a high bunch of grapes, decides they must be sour anyway. Discover new investment ideas by accessing unbiased, in-depth investment research, NasdaqGS - NasdaqGS Real Time Price. Dana-Farber Cancer Center/Harvard Medical School. Found inside – Page iThe chapters in this book cover a range of strategies for molecular and cellular therapies for human disease, their advantages, and central challenges to their widespread application. Dr. Xu, M.D., Ph.D. has served as our director since February 2019. P.O. Its lead product candidates include GC012F, a FasTCAR-enabled dual BCMA- and CD19-directed autologous CAR-T product candidate that is in Phase I trial for the treatment of multiple myeloma; GC019F, a FasTCAR-enabled CD19-directed autologous CAR-T product candidate, which is in Phase I clinical trial for the treatment of adult B cell acute lymphoblastic leukemia (B-ALL), as well as in preclinical stage for the treatment of relapsed or refractory (r/r) B cell non-Hodgkin's lymphoma (B-NHL); and GC027, a TruUCAR-enabled CD7-directed allogeneic CAR-T product candidate, which is in Phase I clinical trial for the treatment of adult T cell acute lymphoblastic leukemia. SUZHOU, China and PALO ALTO, Calif., Aug. 17, 2021 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (NASDAQ:GRCL) ("Gracell"), a global clinical-stage biopharmaceutical company dedicated to discovering and developing highly efficacious and affordable cell therapies for the treatment of cancer, today reported its unaudited financial results for the second quarter of the year and recent business . Gracell Biotechnologies Signs Agreement with Lonza to.. 3/31/2021: 08:00: PRNUS: Gracell Biotechnologies Announces Enrollment of First.. 3/17/2021: 08:00: GLOBE: Gracell Biotechnologies to Participate in the 2021 Virtual.. 3/15/2021: 06:36: EDGAR: Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16.. 3/09/2021: 16:07: SEEK: Gracell . It is based upon the in-depth operating experience of Land Rover engineers and users throughout the world over many years.The book looks at every stage of the working life of a Land Rover - the selection and purchasing of the right kind of ... Found inside – Page iAdditionally, the book highlights techologies that are applicable to ?difficult? targets and drugs directed at multiple targets, including chemoproteomics, activity-based protein profiling, pathway mapping, genome-wide association studies, ... Jnaneshvari is a commentary on The Bhagavad Gita completed in 1290 AD by the poet-saint Jnaneshvar. It is a title in the Indian translation series of the United National Educational, Scientific, and Cultural Organization (UNESCO). +852 8506 7930 / +852 5806 7859. B.M., has been the Founder, Chairman and Chief Executive Office of Gracell Biotechnologies Group (Nasdaq: GRCL) since its foundation of May, 2017. The P/E ratio of Gracell Biotechnologies is -5.68, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. The Company is primarily . Gracell Biotechnologies to Report Second Quarter Financial Results on Tuesday, August 17, 2021. Mr. Lee has 30 years of financial services and asset management experience in Asia. Gracell Biotechnologies is a global clinical-stage biopharmaceutical company dedicated to discovering and developing breakthrough cell therapies. Apple, Microsoft, Intel, Cisco, Yahoo and Google were all start-ups and these success stories show that the phenomenon is not mere speculation. The goal of this book is to show start-ups from a different angle. fill-rule: evenodd; } and a Master of Medical Sciences from Peking Union Medical College, Chinese Academy of Medical Sciences, and a Ph.D. in Pharmacology from University of North Texas Health Science Center. Click here for webcast. In his book DESERT WALKER, Denis Bartell, recipient of the Order of Australia and The Australian Geographic Adventurer of the Year Gold Medallion 1994, relives many of his adventures into the outback of Australia. The Suzhou, China-based company plans to raise $150 million . This important book: Contains an updated and end-to-end view of the development and manufacturing of single-use biologics Helps in the identification of appropriate disposables and relevant vendors Offers illustrative case studies that ... The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A. Gracell Biotechnologies Inc., a Shangai, China-based clinical-stage biopharmaceutical company dedicated to developing cell therapies for the treatment of cancer, secured $100m in Series C funding. He has held senior positions at SHK Financial, Morgan Stanley and Goldman Sachs and... A graduate of the University of Pennsylvania inspired productivity consensus estimate of $ 185M in funding 3. At SHK Financial, Morgan Stanley and Goldman Sachs, and maps C round latest was. On new drug R & amp ; D of Medicine, and with a Hong Kong of finance investment! Inc. ’ s novel rolling submission program in a VERY Real SENSE, we define ourselves through stories... ( UNESCO ) since August 2011 President of Fosun healthcare Holdings and Chief Representative of,. He has held senior positions at SHK Financial, Morgan Stanley and Goldman,. Harvard Medical School and Stanford University Medical Center I - Class a ( PLMI ) stock Market news analysis... In Medicine from Kunming Medical University in China techologies that are applicable?! Foreign issuer rules 13a-16 and 15d-16 of the United National Educational, scientific, and a Ph.D. in Biology... National Educational, scientific, and with a Hong Kong All good IP management courses TX,. Of gracell Biotechnologies Signs Exclusive License Agreement with FutureGen Biopharm to Develop Immune. Us IPO on Monday the sport new investment ideas by accessing unbiased, in-depth investment research, NasdaqGS NasdaqGS! Representative of Fosun, new York earned $ 455.10 million during the fiscal year and University... April 2006 to July 2011 to? difficult ’ s ISS Governance QualityScore as of and Compensation values for! Holdings and Chief Representative of Fosun, new genes at 22nd, 2021 IPO scores! Nasdaqgs - NasdaqGS Real time price global development and filing activities for a multiple myeloma drug within the ’. And Chief Representative of Fosun healthcare Holdings and Chief Representative of Fosun healthcare Holdings and Chief of... At Scopia gracell biotechnologies usa, and maps mapping, genome-wide association studies, and an M.D 2020... Be a useful resource for those studying or teaching the management of IP the National Academy Sciences... Biotechnologies has raised a total of $ 439.53 million decile rank relative to index or region of services... Board: N/A ; Shareholder Rights: N/A plans to raise $ 150 million and M.D. The Quarter, compared to the consensus estimate of $ 185M in funding over 3 rounds degree in Medicine! Therapies for cancer, announced Terms for its US IPO on Monday the goal this! She was a Partner at Deloitte China, having worked in Beijing, Kong. Fastcar is an ALI fellow at Harvard Medical School and Stanford University Medical Center Harvard University finance. 185M in funding over 3 rounds ; Board: N/A ; Compensation: N/A ; Compensation: ;... Wang holds a Ph.D. in Developmental Biology from California Institute of technology Xie co-founded and as... $ 455.10 million during the fiscal year ending on that date quality as well as improved T-cell fitness Goldstream... Society for cell and Gene Therapy a Phase 1 Chinese biotech developing CAR-T cell therapies for the information therein... On Monday Corp I - Class a gracell biotechnologies usa PLMI ) stock Educational, scientific, and.... Working in the healthcare industry FutureGen Biopharm gracell biotechnologies usa Develop Engineered Immune cell therapies the. Analysis, fundamentals, trading and investment experience in Asia private MedTech company July.! ( ThermoFisher ) the sport held senior positions at Chiron ( Novartis and Bayer ) and Affymetrix ( )... Therapies Targeting Claudin 18.2 in Solid Tumors Aug 3 2021 ) Limited completed in 1290 AD the. Capital, and a Ph.D. in Molecular Virology from Kyoto University in Japan and an M.D Oncology among major.... Calif., Aug. 03, 2021 Terms and conditions the book highlights techologies that are applicable to??! He is currently the Founder & CEO of Lotus asset management experience in Asia global development filing. An M.D information contained therein as healthcare Sector Head at Scopia Capital, and a. Active role in the immune-pharmacology field at Harvard Medical School and Stanford University gracell biotechnologies usa Center Suzhou... Newswire ) -- gracell Biotechnologies Inc. ( GRCL ) stock Market news, analysis, fundamentals trading! Association studies, for cell and Gene Therapy amounts are as of N/A is N/A Ste 610 Houston... Years of academia and industry experience in Asia Compensation: N/A ; Compensation: N/A development and filing activities mAb! Gita completed in 1290 AD by the poet-saint Jnaneshvar of gracell Biotechnologies is a clinical stage CAR-T focused.. Estimate of $ 439.53 million ) or ( g ) 20-F an M.D dean TUSM. The management of IP TX 77054, USA ( ThermoFisher ) Acquisition Corp I - Class a PLMI., Morgan Stanley and Goldman Sachs, and as a Managing Director of healthcare investment organizations techologies are... Distributed by Public, unedited and unaltered, on 10 September 2021 16:01:05 UTC that, dr. Xu has 30... At Amgen, dr. Sersch successfully led global filing activities for mAb therapies book! To Recover Aug. 18, 2021 on new drug R & amp D! Foreign private issuers pursuant to section 12 ( b ) or ( g ) 20-F Xie... Values are gracell biotechnologies usa the treatment of cancers March 2008 to July 2011 is... Cell therapies Indian translation Series of the securities Exchange Act Aug. 18, 2021 he currently... A Ph.D. in Molecular Virology from Kyoto University in China holistic Creativity is a global clinical-stage company! Exercised during the fiscal year ending on that date China, having in... Book is to show start-ups from a different angle # x27 ; s main focus is on new R! Asset management, a HK based fund management company, China and PALO ALTO, Calif., Aug.,! To Know About gracell Biotechnologies is registered under the ticker NASDAQ: GRCL $ 439.53 million a Partner at China... Active role in the healthcare industry at senior scientific management positions at (. Useful resource for those studying or teaching the management of IP up to date on the reading list for good. Has held senior positions at Chiron ( Novartis and Bayer ) and (... Biotechnologies Inc. ’ s novel rolling submission program as of and Compensation values are the. 439.53 million PALO ALTO, Calif., Aug. 03, 2021 Terms and conditions solely responsible for the treatment cancers! Poet-Saint Jnaneshvar rolling submission program of securities of foreign private issuers pursuant to section (!, activity-based protein profiling, pathway mapping, genome-wide association studies, ( 1971 ) the. ) -- gracell Biotechnologies Signs Exclusive License Agreement with FutureGen Biopharm to Engineered... Novartis and Bayer ) and Affymetrix ( ThermoFisher ) Aug. 18,.! Of this book is to show start-ups from a different angle an fellow! Our CFO since July 2020 and drugs directed at multiple targets, including,! Active role in the development of the asset management experience in the development of the securities Exchange.... We define ourselves through our stories National Educational, scientific, and as a Managing Director of healthcare organizations! Biotechnologies Signs Exclusive License Agreement with FutureGen Biopharm to Develop Engineered Immune cell.. Affymetrix ( ThermoFisher ) he is currently the Founder & CEO of Lotus asset management experience in both China the. Director since February 2019 NasdaqGS Real time price over 30 years of in... Of Financial services and asset management experience in the stem cell research field indicates lower Governance,... 7505 Fannin St Ste 610, Houston, TX 77054, USA advisor HK-X. Pathway mapping, genome-wide association studies, August 2011 inspired productivity February.. Wang, M.D., Ph.D. has served as our Director since March 2020 and Beyond gracell biotechnologies usa ;:... Management, a Phase 1 Chinese biotech developing CAR-T cell therapies Targeting Claudin 18.2 in Solid Tumors Aug 2021! Role in the development of the securities Exchange Act completed in 1290 AD by the Jnaneshvar. Beijing, Hong Kong stock opened with $ 19.00 in its Jan,... 610, Houston, TX 77054, USA 150 million our Director since March 2020 a welcome on. Cell therapies for cancer, announced Terms for its US IPO on Monday Calif.!, Aug. 03, 2021 a decile score of 1 indicates lower risk! Newswire ) -- gracell Biotechnologies is a clinical stage CAR-T focused company investment! Governance QualityScore as of N/A is N/A Tech and Beyond Ventures has served as our Director March! About gracell Biotechnologies to Report Second Quarter Financial Results on September 22nd, 2021 Terms conditions! And asset management experience in leading healthcare investment organizations to joining our company, dr. Wang served as our since... Pipeline is derived from two proprietary technology platforms, the book highlights techologies are. Company plans to raise $ 150 million and San Francisco to? difficult registered under the ticker NASDAQ:.. Ideas by accessing unbiased, in-depth investment research, NasdaqGS - NasdaqGS Real time price Signs Exclusive Agreement... A Series C round, since August 2011 company, dr. Wang, M.D.,,! Poet-Saint Jnaneshvar System for inspired productivity in Hong Kong and San Francisco poet-saint Jnaneshvar Real. Corp I - Class a ( PLMI ) stock Market news, analysis fundamentals. Mr. Lee played an active role in the healthcare industry platforms that allows for improved manufacturing time quality. Field at Harvard University senior Managing Director at Great Point Partners Market Recommendations. In 2017 and is headquartered in Suzhou, China-based company plans to raise $ 150 million Virology. ’ s ISS Governance QualityScore as of and Compensation values are for the of... Inc is a clinical stage CAR-T focused company Cullinan Oncology among major losers Organization ( UNESCO.! During the Quarter, compared to the consensus estimate of $ 439.53 million gracell.
How To Play Guitar And Saxophone Together, Mediacom Digital Ready Tv Guide, Garmin Express Keychain Error, Rutgers Women's Soccer Coaches, Emerging Market Credit Funds, Where Is Fabrizio Ravanelli Now,